LungCancerStudy Clinical Trial Information

For U.S. residents only.

Non-U.S. residents

Learn About Novartis

Learn About Clinical Trials

Study Description

Screening

Study Centers

Contact/Consent

Novartis is seeking people to participate in a clinical trial(s) testing the safety and effectiveness of Novartis products. Novartis recommends that you consult your doctor before participating in a clinical trial.

For more information about clinical trial participation, click here. Also, for additional information about how Novartis helps to protect the privacy of the personal information that you provide to us, please see the Novartis Privacy Policy.

Please review the details of the clinical trial(s) listed below and click on the one that you feel best suits your (or the participant's) condition.

Brain Metastases from Lung Cancer Study CEPO906A2227

Novartis Oncology is conducting a clinical research study to find out if the study drug, patupilone, is an effective and safe treatment for people who are 18 years or older and have non-small cell lung cancer that has spread to the brain, and that is recurrent in the brain after treatment. The research study is an open-label study, which means that everyone participating in the study will receive the study drug patupilone once every 3 weeks. Patupilone is given by intravenous infusion (directly into a vein) lasting approximately 20 minutes. Patients may remain in the study as long as they and the study doctor think it is in their best interest to participate. The study drug, patupilone, is an investigational drug which has not been approved by the FDA (US Food and Drug Administration) or the EMEA (European Medicines Agency) for the treatment of people with your medical condition.

Advanced Non-small Cell Lung Cancer Study CASA404A2301

The purpose of this study is to determine if adding the study drug ASA404 to standard chemotherapy makes the cancer treatment more effective in patients with newly diagnosed advanced non-small cell lung cancer. The standard chemotherapy regimen that all patients receive in this study is paclitaxel plus carboplatin. Participants will also receive either ASA404 or a placebo (half will receive ASA404, half will receive placebo). The study drug ASA404 is being tested and is not approved for sale in the United States by the U.S. Food and Drug Administration (FDA).